June 24, 2009Open Access

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Key Points

Key points are not available for this paper at this time.

Abstract

Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NCT00516373.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Peter C.C. Fong

David S. Boss

Timothy A. Yap

Journals

New England Journal of Medicine

Actions

Institutions

King's College London

Utrecht University

The Netherlands Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study